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Abstract
The Tudor domain comprises a family of motifs that mediate protein-protein interactions required
for various DNA-templated biological processes. Emerging evidence demonstrates a versatility of
the Tudor family domains by identifying their specific interactions to a wide variety of histone
methylation marks. Here, we discuss novel functions of a number of Tudor-containing proteins
(including JMJD2A, 53BP1, SGF29, Spindlin1, UHRF1, PHF1, PHF19 and SHH1) in ‘reading’
unique methylation events on histones in order to facilitate DNA damage repair or regulate
transcription. This review covers our recent understanding of the molecular bases for histone-
Tudor interactions and their biological outcomes. As deregulation of Tudor-containing proteins is
associated with certain human disorders, pharmacological targeting of Tudor interactions could
provide new avenues for therapeutic intervention.
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Histone modification and its ‘reader’ proteins in gene regulation
In eukaryotic cells, DNA is packaged with core histones H2A, H2B, H3, and H4 to form the
basic building unit of chromatin – nucleosomes. These histones possess many sites for post-
translational modification (PTM) such as methylation, acetylation, ubiquitination, and
phosphorylation, which constitute a hypothetical ‘histone code’ for chromatin organization
and gene regulation [1]. It has been postulated that functional interpretation of histone PTMs
is executed at least in part by so-called histone ‘reader’ proteins, which use structurally
conserved domains to recognize and engage histone PTMs in a sequence- and modification-
specific fashion. ‘Reader’-mediated chromatin interaction helps recruit and/or stabilize the
associated multi-protein complexes to specific loci to further alter chromatin structure and
regulate DNA-dependent processes in various biological contexts [2–4]. Deregulation in
interpretation of histone PTMs has been causally linked to the development of various
human diseases including cancer [5–7], immune dysfunction [8, 9], and neurological
disorders [8, 10]. Therefore, dissecting the biochemical bases for histone-‘reader’
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interactions could promote a deeper understanding of the fundamental mechanism that
underlies gene regulation and pathogenesis.
A number of protein domain families have been identified that specifically recognize histone
PTMs. For example, bromodomains bind histone lysine acetylation in a promiscuous
manner [2, 4, 11], 14-3-3 and BRCT (BRCA1 C-terminus) domains bind to histone serine or
threonine phosphorylation [2, 4], and different subsets of PHD (plant homeodomain) finger
motifs are able to recognize different degrees of methylation status at histones H3 lysine 4
[2, 4, 12–17]. Furthermore, a large family of so-called Royal family domains including
Tudor, chromo, MBT (malignant brain tumor), and PWWP (pro-trp-trp-pro) domains have
been shown to interact with methylated histone tails [2, 4]. In this review, we focus on
recent studies that reveal the multifaceted capacities of various Tudor domains in ‘reading’
different histone methylation marks on chromatin and discuss how these Tudor-containing
‘readers’ and associated protein complexes further direct chromatin state-dependent
regulation of gene transcription and DNA damage repair.
Tudor domain as ‘readers’ of histone PTMs
The Tudor domain was named after the Drosophila tudor (tud) gene identified in a screen for
maternal-effect recessive lethality or sterility [18]. Drosophila tud contains eleven repeats of
a conserved motif, subsequently termed Tudor, which appears in many proteins throughout
various species [19, 20]. The Tudor domain typically contains approximately sixty amino
acids that comprise 4–5 antiparallel β-strands to form a barrel-like structure. A number of
Tudor-containing proteins were found to interact with methylated arginine residues in non-
histone proteins involved in the regulation of RNA metabolism, alternative splicing, small
RNA pathways, or germ cell development [21, 22], whereas other Tudor domains were
shown to form a chromodomain-like cage [23] at their surfaces to accommodate a
methylated lysine [24–26]. Among the approximately 30 mammalian Tudor-containing
proteins, 53BP1 and JMJD2A were the first ones that were shown to harbor histone
methylation-binding capacities via Tudor [27–29]. Recent studies have identified novel
functions of a number of other Tudor-containing proteins including SGF29 [30, 31],
Spindlin1 [32, 33], UHRF1 [34–37], PCL family proteins (PHF1 [38–40] and PHF19 [38,
40–42]), and SHH1 [43], in ‘reading’ a variety of different histone methylations
(summarized in Table 1); in addition, recent works also demonstrated that JMJD2A and
53BP1 binding to dimethylated histone H4 lysine 20 (H4K20me2) is critical for regulation
of cellular response to DNA damage [44, 45]. In the following sections, we discuss our
current understanding of the molecular basis and biological function of these new Tudor-
histone interactions.
Hybrid tandem-Tudor domain as a histone PTM ‘reader’
JMJD2A, JMJD2B and JMJD2C, three members of the Jumonji domain – containing 2
(JMJD2) family of proteins, all contain a JmjN-JmjC domain that specifically removes tri-/
di-methylation marks on histone H3 Lys9 and Ly36 (H3K9me3/2 and H3K36me3/2), two
PHD fingers, and two Tudor domains in tandem (termed tandem-Tudor) near their C-termini
(Table 1) [46]. Although the tandem-Tudor domain is not essential for demethylating
activities [47], it harbors binding activities towards tri-methylation of histone H3 Lys4 and
histone H4 Lys20 (H3K4me3 and H4K20me3), indicating a chromatin-targeting mechanism
for these enzymes [28, 48].
Structurally, the two Tudor domains in the JMJD2A tandem-Tudor inter-digitate with two
shared β-strands to form a bilobal, saddle-shaped structure, with each hybrid lobe
resembling a canonical Tudor fold (Figure 1A) [28]. The second lobe uses a cluster of
aromatic residues, F932, W967 and Y973 to establish an open ‘cage’-like structure for
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binding the side chain of H3K4me3 or H4K20me3 (Figure 1A, left and right panels) [28].
The two complexes share high similarity in the overall hybrid lobe structure, the aromatic
‘cage’, and the binding affinities (Table 1). The H3 and H4 peptides, however, contact to the
Tudor domains in opposite orientations and at different surfaces of the second hybrid Tudor
domain (Figure 1A, left versus right) [48].
The JMJD2A tandem-Tudor domain also binds in relatively high affinity to H4K20
dimethylation (H4K20me2) (Table 1), a histone PTM known to mark the site of DNA
damage and to recruit a critical DNA repair factor 53BP1 (which also uses a tandem-Tudor
domain to bind H4K20me2; see the next section) [45]. A recent study showed that JMJD2A
and JMJD2B proteins engage H4K20me2 and ‘mask’ the accessibility of this histone PTM
to 53BP1 in non-damaged cells (Figure 2A) [45]. Upon DNA damage, the E3 ubiquitin
ligases RNF8 and RNF168 degrade JMJD2 via an ubiquitination-dependent mechanism,
thus allowing exposure of H4K20me2 and induction of 53BP1-mediated loci formation
(Figure 2A) [45]. This highlights an elegant mechanism to specifically expose H4K20me2 at
DNA damage sites where 53BP1 is recruited. Taken together, binding to histone
methylation by the JMJD2A Tudor controls DNA damage-induced cellular response by
antagonizing 53BP1.
Independent tandem-Tudor domain as a histone PTM ‘reader’
53BP1 Tudor, a ‘reader’ of methylated H4K20—The mammalian 53BP1 and its yeast
homologue Crb2 are evolutionarily conserved checkpoint proteins involved in DNA damage
response. ATM family kinases phosphorylate 53BP1/Crb2 upon insults such as DNA
double-strand breaks (DSB). 53BP1/Crb2 subsequently re-localizes to DSB sites and
promotes formation of the ionizing radiation-induced foci, an assembly of numerous DNA
repair and checkpoint proteins [49]. The tandem Tudor domain of 53BP1 has been shown to
bind damage-induced dimethylation of p53 and facilitate p53 accumulation during DNA
repair [50, 51]. Radiation sensitivity and elevated tumor risk in 53BP1-deficient mice lend
credence to the role of this protein in DNA damage response [52]. Recruitment of 53BP1
occurs, in part, through its association with methylated H4K20 (H4K20me) at DSB sites
(Figure 2B) [27, 29, 53], a process negatively controlled by JMJD2A (Figure 2A). 53BP1
promotes the non-homologous end-joining (NHEJ) repair pathway whereas BRCA1
antagonizes 53BP1 to promote homologous recombination (HR) [54–56]. Biochemical and
structural analysis indicate that a conserved tandem-Tudor domain of 53BP1 (Table 1) and
Crb2 preferentially interacts with H4K20me2, though it also binds to H4K20me1 [29]. The
53BP1 tandem-Tudor domain forms two independently folded structures, which is different
from the JMJD2A hybrid-tandem Tudor domain described above, despite their sequence
similarity. The H4K20me2-binding cage comprises four aromatic residues, W1495, Y1502,
F1519, and W1523, and an aspartic residue D1521, all of which reside in the first Tudor
domain (Figure 1B). These aromatic residues interact with the dimethyllysine ammonium
group of H4K20me2 through van der Waals and cation-π interactions, while a direct
hydrogen bond formed between the amino proton of H4K20me2, and the carboxylate group
of D1521 dictates selectivity for di- or mono-methylation over tri-methylation [29].
Mutations of these critical residues impaired binding to H4K20me2 and also compromised
efficient 53BP1 targeting to DSB [29], which is in agreement with the genetic interaction
between Crb2 and the H4K20 site observed in yeast [27, 53, 57].
The 53BP1 Tudor motif also forms extensive contacts with histone residues adjacent to
H4K20me2 such as H4K16 [44] and H4H18 [29]. It is believed that association with
adjacent histone sequences contributes to binding specificity, selectivity, and/or affinity,
which is a common theme for almost all of the structurally defined histone methylation-
‘readers’, including Tudor. Indeed, a recent study showed that recognition of H4K20me2 by
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53BP1 is inhibited by TIP60-mediated acetylation of H4K16 (Figure 2B) [44]. Essentially,
H4K16 acetylation disrupted a critical salt bridge formed between H4K16 and an acidic
residue (E1551) of 53BP1 Tudor, and therefore destabilized 53BP1 binding to H4K20me2
[44]. As a result, 53BP1-mediated NHEJ is inhibited, and BRCA1-mediated HR takes over
for repair (Figure 2B). Taken together, these studies demonstrate a direct role of 53BP1-
mediated ‘read-out’ of H4K20me2 for promoting DNA repair, and the histone PTM contexts
at sites of DSBs provide an elaborate regulatory mechanism for controlling 53BP1
association and dissociation, which fine-tunes the decision-making among different options
available for repair.
SGF29 Tudor, a ‘reader’ of H3K4me3/2—SAGA (Spt–Ada–Gcn5 acetyltransferase) is
an evolutionarily conserved multi-protein complex that facilitates gene transcription by
mediating histone acetylation and deubiquitination [58]. Among SAGA subunits, SGF29 is
the only one that contains a tandem-Tudor domain that is conserved across species from
yeast to human [30]. The SGF29 tandem-Tudor domain (Table 1) has recently been
identified as an H3K4me3/2-specific ‘reader’ by mass spectrometry-based screening [31].
H3K4me3 is its preferred ligand, with a Kd of about 1–4 μM [30, 31], which is consistent
with ChIP-sequencing studies showing that SGF29 localizes to gene promoters and largely
overlaps with H3K4me3 [31]. Structural analyses further demonstrate the SGF29 tandem-
Tudor domains form independently but pack tightly against each other with interactions
between the first two β-strands of each motif (Figure 1C) [30]. When bound by SGF29,
H3K4me3 is anchored in a negatively charged ‘pocket’ that consists of three conserved
aromatic residues, Y238, F264, and Y265, and an acid residue D266, at the surface of the
second Tudor domain (Figure 1C). Multiple interactions including cation-π, van der Waals,
and hydrophobic interactions, as well as a salt bridge between H3K4me3 and the aromatic
‘pocket’, establish the intermolecular binding [30]. Similar to H3K4me3/2-engaging PHD
fingers [2, 8, 15], the SGF29 Tudor domain also interacts with the N-terminus of H3
including residues A1 and R2, which contributes to binding specificity towards H3K4me3
[30]. Knockdown of SGF29 or introduction of point mutations at its aromatic ‘pocket’
abolishes interaction between H3K4me3 and SAGA complexes, leading to loss of SAGA
binding at target promoters and decreased acetylation of H3K9, H3K14 and H3K18 [30, 31].
Taken together, these observations demonstrate a critical role for the SGF29 tandem-Tudor
domain in linking SAGA complexes to H3K4me3/2-marked promoters to mediate
transcriptional regulation through subsequent chromatin modifications (Figure 2C).
Spindlin1 Tudor, a ‘reader’ of H3K4me3—The nucleolar protein Spindlin1 contains
three Tudor-like domains in tandem as revealed by its crystal structure [59]. Initially,
Spindlin1 was identified as an H3K4me3-interacting factor in a proteomics screen using
protein affinity purification with pre-methylated nucleosomes [60]. A later measurement of
Spindlin1 interaction with H3K4me3 indeed revealed a high affinity, with a Kd of ~0.3–0.8
μM (Table 1) [32, 33]. Structural analyses show the second Tudor domain is the sole
contributor to H3K4me3 association, with a binding ‘cage’ consisting of four aromatic
residues F141, W151, Y170, and Y177 that tap the H3K4-trimethylated side chain (Figure
1D) [32]. Other histone residues, including H3A1, H3R2, and H3R8, form hydrogen bonds
with several negatively charged residues from the second Tudor domain [32]. These studies
also show that all these interactions confer a tight binding of Spindlin1 to the H3K4me3-
‘marked’ promoters among the ribosomal DNA gene repeats in the nucleolus, where
Spindlin1 facilitates rRNA transcription (Figure 2D) [32, 33]. However, the mechanism by
which Spindlin1 stimulates the rRNA gene expression is currently unknown.
UHRF1 Tudor, a ‘reader’ of H3K9me3—Ubiquitin-like with PHD and RING finger
domains 1 (UHRF1) contributes to the maintenance of DNA methylation by recruiting DNA
Lu and Wang Page 4













methyltransferase DNMT1 to replication forks [61, 62]. UHRF1 contains multiple
conserved protein motifs, including an ubiquitin-like domain (UBL) at N-terminus, followed
by a tandem-Tudor domain, a PHD finger, a SET- and RING-associated (SRA) domain, and
a RING domain at C-terminus (Table 1). Previously, it was demonstrated that the UHRF1
SRA domain specifically recognizes replication-induced, hemi-methylated CpG
dinucleotides (Figure 2E), providing a mechanism for targeting DNMT1 to the newly
synthesized DNA fibers in order to restore the cellular level of DNA methylation [63–65].
Several recent studies further revealed an equally critical role of the UHRF1 tandem-Tudor
domain for maintenance of DNA methylation [34, 36, 37, 66, 67]. These studies show the
UHRF1 tandem-Tudor domain binds to H3K9me3 with high affinity (Table 1). Indeed, such
binding is required for UHRF1-mediated recruitment of DNMT1 to heterochromatic regions
to promote DNA methylation (Figure 2E) [35, 66, 67]. The crystal structure of UHRF1
tandem-Tudor domain plus PHD finger in association with H3K9me3-containing histone H3
peptides was solved [35]. Similar to SGF29, the two UHRF1 Tudor domains in tandem also
packs tightly against each other using their first two β-strands, while the first Tudor
accommodates the H3K9me3 side chain using an aromatic ‘cage’ formed by F152, Y188
and Y191 (Figure 1E) [35]. Genetic complementation assays performed among Uhrf1-null
ES or UHRF1-knockdown cells demonstrate that the UHRF1 mutants, deficient in binding
to either H3K9me3 or hemi-methylated CpG, only exhibit a partial or subtle defect in their
association with heterochromatin and in their abilities to maintain DNA methylation,
whereas those with deficiencies in both show a much more dramatic defect with a complete
failure in rescuing loss of DNA methylation [34, 36]. Together, these studies demonstrate a
multilayered, compensatory mechanism provided by various structural modules of UHRF1
in order to enforce an efficient chromatin targeting and to maintain the fidelity and level of
DNA methylation (Figure 2E; also see section of ‘multivalent readout of histone PTMs’
below for further discussion of the linked Tudor and PHD modules of UHRF1).
Single Tudor domain as a histone PTM ‘reader’
PHF1 and PHF19 Tudor, ‘readers’ of H3K36me3/2—The polycomb-like (PCL)
protein family acts as an accessory component of PRC2 (Polycomb Repressive Complex-2),
the complex that catalyzes tri-methylation of histone H3 Lys27 (H3K27me3) to repress gene
expression [68, 69]. Three mammalian PCL members, PHF1 (also known as PCL1), MTF2
(also known as PCL2), and PHF19 (also known as PCL3), all contain a single Tudor motif,
two PHD fingers (Table 1), and a C-terminal chromo-like domain [42]. In vitro studies
suggest that PCL proteins modulate PRC2 enzymatic activities and appear to help recruit
PRC2 to a subset of target genes important for development and differentiation [70–76].
Recently, a flurry of reports further demonstrated that the Tudor domain of PHF1 and
PHF19 specifically ‘reads’ H3K36me3/2, a histone PTM that marks the gene body of
actively transcribed genes [38, 39, 41, 42]. Binding to H3K36me3 by the PHF1/PHF19
Tudor (Table 1)[38–40, 42] is much tighter than that by the previously reported H3K36me3
‘readers’ such as the chromodomain of Eaf3 [77, 78] and PWWP domains[79, 80].
Structural analyses of the PHF1 and PHF19 Tudors reveal two highly similar β-barrel
structures (Figure 1F–G) with each comprising five antiparallel β-strands [38, 39, 42]. The
trimethylammonium side chain of H3K36me3 fits into an aromatic ‘cage’ at one end of the
β-barrel (Figure 1F–G) [38, 39]; the histone H3 residue T32 to R40 make additional contacts
to Tudor, which include a salt bridge formed between H3K37 and an acidic residue of Tudor
(E66 of PHF1 or E75 of PHF19) [38, 39, 42]. Biochemically, extensive direct interactions
between PHF1/PHF19 Tudors and the histone sequences surrounding H3K36me3 contribute
to their binding specificity and affinity.
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Using overexpression and knockdown of PHF1/PHF19, these recent studies collectively
showed that ‘reading’ of H3K36me3/2 by PHF1/PHF19 Tudors mediates targeting and/or
spreading of PRC2 complexes to a number of H3K36me3-containing loci among HeLa or
pluripotent stem cells (Figure 2F) [38, 41, 42]. Mutations at the ‘cage’ residues of PHF1/
PHF19 Tudors abolished the H3K36me3/2 binding and prevented PRC2-mediated
repression of certain development genes such as Hox and Fgf [38, 41, 42]. Furthermore,
PHF19 or the PRC2 complex was found to be associated with an H3K36me3 demethylase
NO66 [41] or coexisting with an H3K36me2 demethylase KDM2B [42, 81] at a subset of
PRC2 target genes, promoting a simultaneous H3K36 demethylation and H3K27
methylation in order to complete conversion from a state of active gene transcription to de
novo silencing. Interestingly, a recent mass spectrometry-based study identified a form of
asymmetrically methylated mono-nucleosomes that carry both H3K36me3/2 and
H3K27me3/2 on two separate H3 tails in ES or HeLa cells [82], and such a bivalent mono-
nucleosomes may represent the sites where PHF1/19-PRC2 complexes act [38]. However,
the overall biological role of the PCL proteins is quite complex, as it has recently been
shown that in vitro, binding of the PHF1 Tudor domain to H3K36me3-containing
nucleosomes decreases the methyltransferase activity of PRC2 [39]; furthermore, Tudor-
mediated binding to H3K36me3/2 was also found required for efficient recruitment of PHF1
to sites of DSBs during response to DNA damage [39], but the exact function of PHF1 in
DNA repair remains to be studied. Taken together, these studies provide a novel mechanism
for PRC2 complexes to gain access and target to the chromatin regions that harbor active
genes, where PRC2 and associated factors establish de novo transcriptional silencing that is
required for differentiation and development.
LBR Tudor, a ‘reader’ of heterochromatin and H4K20me2—The Lamin-B receptor
(LBR) is an inner nuclear membrane protein that plays a crucial role in functional
organization of nuclear architecture, particularly, in the formation and maintenance of
nuclear peripheral heterochromatin [83]. In human, LBR mutations cause Pelger-Huët
anomaly which is characterized by an aberrant neutrophil nuclear shape [84]; in murine
models, deletions of LBR and Lamin-A/C lead to loss of peripheral heterochromatin, an
inverted architecture with heterochromatin localizing to the nuclear interior, and
perturbation in expression of genes associated with development [85]. The N-terminal part
of LBR was known to be responsible for heterochromatin association [83], and contains a
Tudor domain (Table 1). Deletion of Tudor renders LBR more mobile at nuclear envelope
[84, 86]. A recent study reported the LBR Tudor domain binds H4K20me2, a
heterochromatin-associated histone PTM [84], although another study indicates that the
domain confers a ‘chaperone-like’ binding to histones [86]. These studies suggest a role of
Tudor, possibly via interaction to heterochromatin PTMs, for LBR-mediated
heterochromatin formation at the nuclear peripheral. Further examination of LBR Tudor and
its binding partners needs to be performed.
Multivalent read-out of histone PTMs by Tudor and linked ‘reader’ modules
Tudor domains not only engage their preferred histone PTMs by a structurally defined
‘cage’ or ‘pocket’ (Figure 1), but also establish direct contacts to the surrounding histone
sequences. The combination of these interactions contributes to the binding specificity,
selectivity, and affinity of Tudor-domain proteins. In addition, Tudor domains often exist in
proximity to other putative ‘reader’ domains (Table 1), indicating multivalent engagement
of different histone PTMs by the linked ‘reader’ modules [3]. A prominent case of
multivalency is the ‘PHD-linker-bromodomain’ cassette of BPTF, where the two separated
‘reader’ domains harbor capacities to bind to H3K4me3 and H4K16ac, respectively. The
helical linker region in between dictates a precise relative orientation of two modules,
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ensuring a simultaneous, combinatorial read-out of the two PTMs located at separated
histone tails within the same mono-nucleosome [3, 87].
Here, we discuss recent advances indicating a new mode of multivalent recognition utilized
by the ‘tandem-Tudor-linker-PHD’ cassette of UHRF1 (Table 1). Initially, studies of
individual domains within this cassette showed the UHRF1 tandem-Tudor and PHD finger
motif engage H3K9me3 and the N-terminus of histone H3, respectively [66, 88]. However,
examination of the whole domain cassette revealed that the inter-modular linker directly
interacts with ‘reader’ modules and facilitates formation of a compact, ring-shaped
architecture [35, 37, 89]. In this structure, the N-terminus of H3 (A1-R2-T3-K4) is engaged
by the PHD finger, the residues 5–7 of H3 engaged by neither PHD nor Tudor, and only a
rather short histone sequence (R8-K9me3) bound to Tudor (Figure 1E and 2E) [35, 37, 89].
As a result of such structural arrangement, binding to H3 primarily relies on the PHD finger,
whereas Tudor appears only to confer additional selectivity for H3K9me3 [35, 37, 89].
Using a series of elegantly designed H3 peptides and UHRF1-mutants, a recent study
provided supporting evidence for a mode of multivalent binding where the linked UHRF1
modules appear to scan from the extreme N-terminus of H3 towards PTMs located
downstream [37], and this sequential ‘read-out’ of histone PTMs proposed for UHRF1
differs from a simultaneous, combinatorial mode of engagement [87].
Interestingly, the positioning of H3 in complex with the individual UHRF1 tandem-Tudor
domain [66] is distinct from that observed in linked modules described above; in the former
structure, residues 1–9 of H3 establish extensive contacts to a groove on the surface of
Tudor[66], whereas this H3-binding groove is masked by the inter-modular linker and
becomes non-accessible to H3 in the latter[35, 89]. These studies demonstrate an essential
role of the linker in defining and reshaping the mode of binding to histones. In support,
mutagenesis of two critical linker residues, R295 and R296, disconnect the coordinated
action between ‘reader’ modules, leading to abrogation of combinatorial binding to H3/
H3K9me3, reduction in chromatin localization of UHRF1 and loss of global DNA
methylation [35]. Phosphorylation of S298, a conserved target site of PKA kinases within
the linker, show a similar phenotype, indicating that modulation of the linker region might
serve as a switching mechanism to regulate UHRF1 activities under a physiological
condition [35]. Of note, unlike UHRF1, the PHD finger adjacent to PHF1/19 Tudors does
not exhibit detectable histone-associating activities and does not alter binding to H3K36me3
by Tudor [40]. Taken together, these studies show adjacent ‘reader’ modules can evolve and
form a high-order structure to establish various delicate mechanisms for multivalent ‘read-
out’ of chromatin PTMs.
Targeting Tudor-histone interactions as potential therapeutic interventions
Many human diseases including cancer, possess mutations that deregulate chromatin PTM-
specific ‘writers’, ‘erasers’ or ‘readers’[5, 8]. Pharmacological manipulation of these
‘writing’, ‘erasing’, and ‘reading’ processes has recently become an area of intense
investigation [5, 90, 91]. Recently, small-molecule inhibitors for the BET bromodomain
family of acetylation ‘readers’ have shown early promise in treatment of the genetically
defined midline carcinoma [92] and hematopoietic malignancies [93–95]. Similar
compounds could be developed to target other epigenetic ‘readers’ that are disease-
associated [5, 6, 90, 91]. Notably, many of Tudor-containing ‘readers’ were found to be
deregulated in cancer— all three Tudor-containing JMJD2 proteins are frequently
overexpressed in various cancers [96], altered expression of UHRF1 is commonly found in
cancer [97], and the recurrent chromosomal translocation of PHF1 and up-regulation of
PHF19 were reported among endometrial sarcoma and solid tumors, respectively [98, 99].
Designing inhibitors that target the Tudor-histone binding interfaces may provide a unique
tool not only for dissecting the role of these interactions in normal biological processes, but
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also for studying their relevance to pathogenesis. For instance, UHRF1 inhibitors could
represent an alternative way to inhibit DNA methylation, in addition to the currently
available DNA demethylating agents used for cancer therapies [100]. A recent study has
developed the first-in-class inhibitor for histone methylation ‘readers’ [101]. Taken together,
pioneering studies support druggability of histone methylation ‘readers’, and investigation is
needed to develop potent, specific inhibitors that target Tudor-histone interactions.
Concluding remarks
Dissecting the fundamental mechanism by which chromatin modifications regulate various
biological processes has become a major focus in chromatin biology. Studies aimed at
understanding the interpretation of various chromatin modifications have focused on
identifying novel epigenetic effectors. Mass spectrometry-based protein identification
following pull-down with pre-modified histone peptides or nucleosomes [17, 31, 38, 60,
102, 103] has proven powerful in identifying novel, site-specific ‘readers’ for chromatin
PTMs when combined with the high-throughput peptide or protein array technologies [38,
104, 105]. Subsequent structural and biological elucidation of these chromatin-‘reading’
modules allows a deeper understanding for the molecular bases that underlie processes
regulated by histone-‘reader’ interactions. Recent identification of the Tudor family as
versatile effectors of histone methylation re-enforces this theme and expands our current list
of epigenetic ‘readers’. Future experiments should help characterize linked modules, and
their role in combinatorial ‘read-out’ of multiple PTMs. For instance, a novel, dual histone-
‘reading’ activity (binding of unmethylated H3K4 and H3K9 methylation) has recently been
identified in a cryptic, tandem Tudor-like domain of SHH1 (SAWADEE homeodomain
homolog-1) (Figure 1H) in Arabidopsis, and this activity is required for maintaining the
level of siRNAs and RNA-directed DNA methylation in this organism [43]. In addition,
evidence starts to emerge showing that Tudors also ‘read’ lysine methylation of non-histone
partners, in addition to arginine methylation[21, 22]. For example, the 53BP1 tandem-Tudor
domain binds to H4K20me3 and dimethylated p53 [50, 51], and that of PHF20 has been
shown to bind to lysine dimethylation of histones [106] and p53 [107]; in the latter case,
PHF20 binding to p53 stabilizes p53 and promotes its activation during DNA damage
response [107]. Similarly, the Tudor domain of TDRD3 recognizes arginine dimethylation
present in non-histone proteins such as the alternative splicing factor SmB [108] and in
histones, such as asymmetric dimethylation of H4R3, H3R17 and H3R2 (Table 1) [105,
109], and studies have demonstrated a critical role of the TDRD3 Tudor domain in
facilitating gene transcription[105]. It has become increasingly critical to dissect effects that
are dependent on chromatin PTM and those that are directed through non-histone partners.
Lastly, small-molecule inhibitors that specifically target epigenetic ‘readers’ hold promise
for novel therapeutic means. Initial development of compounds could take advantage of the
solved Tudor domain structures, while parallel efforts could be directed at examining the
causality of Tudor-containing ‘readers’ in oncogenesis or other pathologies. These new
pharmacological tools could allow a dynamic manipulation of histone-‘reader’ interactions
and prove to be useful as therapeutic interventions.
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• Evidence reveals the versatility of Tudor in ‘reading’ various histone
methylation.
• Tudor domain uses an aromatic ‘cage’ to accommodate its histone methylation
ligand.
• Tudor and adjacent modules can combinatorially ‘read’ multiple histone
modifications.
• Tudor-histone interaction is critical for regulating various DNA-templated
processes.
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Figure 1. Structure of Tudor domains bound to their histone lysine methylation ligands
Panels shown are the structure for a tandem-Tudor domain of JMJD2A in complex with
H3K4me3 (panel A, left) or H4K20me3 (panel A, right); a tandem-Tudor domain of 53BP1
in complex with H4K20me2 (panel B); that of SGF29 (panel C) and Spindlin1 (panel D) in
complex with H3K4me3; the linked Tudor-PHD modules of UHRF1 in complex with
H3K9me3 and the unmodified N-terminus of histone H3 (panel E); a single Tudor motif of
PHF1 (panel F) or PHF19 (panel G) in complex with H3K36me3; and a cryptic, tandem
Tudor-like module of SHH1 in complex with H3K9me3 and the unmodified H3K4 (panel
H). The Tudor sequences and histone peptides are colored in green and yellow, respectively.
Identification of each of the aromatic residues involved in the formation of histone
methylation-binding ‘cage’ or ‘pocket’ are labeled with their side chains colored in purple.
The Protein Data Bank (PDB) accession numbers for structures presented in panels A to H
are 2GFA, 2QQS, 2LVM, 3ME9, 4H75, 3ASK, 4HCZ, 4BD3, and 4IUT, respectively.
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Figure 2. Functional ‘read-out’ of histone methylation by Tudor-containing proteins and their
associated complexes
(A) JMJD2A Tudor domain (in red) binds to H4K20me2 in undamaged cells and prevents
the damage-associated formation of 53BP1 loci. Upon DNA damage, E3 ubiquitin ligases
RNF8 and RNF168 promote JMJD2A ubiquitination and degradation at sites of DNA
damage, which allow 53BP1 to bind to H4K20me2 and form loci at the damaged sites.
(B) During cellular response to DNA damage, recognition of H4K20me2 by the 53BP1
Tudor (in red) helps to efficiently recruit 53BP1 to sites of double-strand DNA breaks
(DSB) where 53BP1 promotes the non-homologous end joining (NHEJ) repair pathway.
TIP60-mediated H4K16 acetylation inhibits 53BP1 interaction to H4K20me2, blocks 53BP1
recruitment, and promotes BRCA1-mediated homologous repair (HR) pathway.
(C) ‘Reading’ H3K4me3 and the N-terminus of H3 (exampled by A1R2) by the SGF29
Tudor (in red) is critical for recruitment of GCN5 and other SAGA complex components to
target gene promoters where GCN5-SAGA promotes histone acetylation and gene
transcription.
(D) The nucleolar protein Spindlin1 utilizes a Tudor domain (in red) to recognize H3K4me3
and the surrounding H3 residues (exemplified by H3R2 and H3R8), which facilitates its
recruitment to active rDNA genes and its promotion of rRNA expression.
(E) A multivalent engagement of the unmodified N-terminus of histone H3 (shown as
A1R2T3K4), H3K9me3, and the hemi-methylated DNA by the linked UHRF1 PHD finger
(in green), Tudor (in red) and SRA (in pink) motifs, respectively, helps to recruit UHRF1
and associated DNMT1 to heterochromatin. DNMT1 subsequently methylates the newly
synthesized DNA and maintains a normal cellular level of DNA methylation.
(F) Binding to H3K36me3 by the PHF1 or PHF19 Tudor (in red) provides a novel
mechanism for recruiting PRC2 to a subset of actively transcribed genes, which results in
optimal H3K27me3 and repression of gene transcription.
Ac, acetylation; Me, methylation; Ph, phosphorylation; rDNA, ribosomal DNA; All Tudor-
containing proteins are colored in light green.
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